GlassScriptPhysician profile
Jeffrey A Miller
NPI 1184725897
$13,906.99
in general payments reported to CMS, 2019-2025
50 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,563 · 2020: $1,884 · 2021: $1,973 · 2022: $2,200 · 2023: $2,137 · 2024: $1,889 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,911 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,910.64 |
| Education | $375.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,066.24 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,200.51 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $1,111.96 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $990.71 | 2019-2025 | Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.59 | 2019-2025 | Stiolto Respimat, Ofev, Jascayd |
| Avadel Cns Pharmaceuticals, LLC | $513.26 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $502.64 | 2020-2025 | Wakix |
| Novo Nordisk INC | $452.56 | 2019-2024 | Wegovy |
| Amgen INC. | $427.28 | 2021-2025 | Tezspire, Repatha |
| Regeneron Healthcare Solutions, INC. | $407.19 | 2019-2025 | Dupixent |
| Insmed, INC. | $348.78 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $339.96 | 2019-2025 | |
| Philips North America LLC | $330.68 | 2019-2025 | Vest Therapy Und |
| Idorsia Pharmaceuticals US INC | $252.43 | 2022-2024 | Quviviq |
| Mylan Specialty L.P. | $197.86 | 2019-2024 | Yupelri |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.